Inhibitor-based methods for detection of plasmid-mediated AmpC beta-lactamases in Klebsiella spp., Escherichia coli, and Proteus mirabilis.
Non-beta-lactam inhibitor-based methods were evaluated for detecting plasmid-mediated AmpC beta-lactamases in Klebsiella spp., Escherichia coli, and Proteus mirabilis. Using CLSI methodology and disks containing cefotetan alone and in combination with 400 mug of boronic acid, 9 of 10 positive control strains and 54 of 55 AmpC-PCR-positive clinical isolates were detected. Importantly 71% and 40% of these clinical isolates were susceptible by routine testing to ceftriaxone and ceftazidime, respectively. Boronic acid disks also enhanced detection of expanded-spectrum beta-lactamases in AmpC producers.
Coudron
Philip E
PE
Pathology and Laboratory Medicine Service/113, McGuire Veterans Affairs Medical Center, Richmond, VA 23249-0001, USA. Philip.Coudron@med.va.gov
D001426:Bacterial Proteins / Q000032:analysis* / Q000037:antagonists & inhibitors / Q000235:genetics; D001897:Boronic Acids / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D004926:Escherichia coli / Q000187:drug effects / Q000201:enzymology*; D006801:Humans; D007709:Klebsiella / Q000187:drug effects / Q000201:enzymology*; D008826:Microbial Sensitivity Tests; D010957:Plasmids / Q000502:physiology*; D011513:Proteus mirabilis / Q000187:drug effects / Q000201:enzymology*; D065093:beta-Lactamase Inhibitors; D001618:beta-Lactamases / Q000032:analysis* / Q000235:genetics
D001426:Bacterial Proteins; D001897:Boronic Acids; D004791:Enzyme Inhibitors; D065093:beta-Lactamase Inhibitors; C048795:AmpC beta-lactamases; D001618:beta-Lactamases